Welcome to our dedicated page for Beigene SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode the science-heavy language in BeiGene’s oncology disclosures? Each 10-K details dozens of global clinical trials, milestone obligations, and R&D burn-rates that can stretch past 300 pages. Finding when cash runs out—or which trial just moved to Phase III—takes time investors rarely have.
Stock Titan solves that problem. Our AI-powered summaries turn BeiGene SEC filings explained simply, highlighting the exact paragraph that answers questions like “How much did R&D rise this quarter?” or “Which licensing partner triggered a milestone?” Whether you need the BeiGene annual report 10-K simplified, a BeiGene quarterly earnings report 10-Q filing, or BeiGene 8-K material events explained, the platform delivers real-time alerts the moment they hit EDGAR. You’ll also see BeiGene Form 4 insider transactions real-time, complete with context so you understand why an executive sold shares before a data readout.
Dig deeper without getting lost: track BeiGene insider trading Form 4 transactions to spot buying trends, scan BeiGene proxy statement executive compensation to evaluate alignment, and run instant BeiGene earnings report filing analysis to compare pipeline spending quarter-over-quarter. From understanding BeiGene SEC documents with AI to monitoring BeiGene executive stock transactions Form 4, every filing type is covered and linked to the metrics that matter—so you make informed decisions faster.
BeOne Medicines Ltd. (ONC) – Form 4 filing dated 31-Jul-2025
SVP & General Counsel Henry Chan Lee reported a mandatory tax-related sale of 920 American Depositary Shares (ADS) on 30-Jul-2025 at a weighted-average price of $304.6008. Each ADS equals 13 ordinary shares, so the transaction represents the disposition of roughly 11,960 ordinary shares equivalent.
The ADS were automatically sold to cover withholding taxes upon vesting of a previously granted RSU award that vests 25 % annually on the anniversary of 29-Jul-2022, with possible acceleration on certain termination events. Following the sale, Lee continues to hold 266,474 ordinary shares directly.
- No derivative security activity was reported.
- The filing was executed by attorney-in-fact Qing Nian.
The transaction appears routine and driven by tax-withholding obligations rather than discretionary selling, limiting its market significance.
BeOne Medicines (ONC) filed a routine Form 4 showing Global Head of R&D Lai Wang sold 1,028 American Depositary Shares on 06/23/2025 at $260 each (≈ $0.27 million) to cover tax withholding linked to vested RSUs. After the sale, he still holds 1,023,529 ordinary shares directly and 731,965 indirectly via Wang Holdings LLC—together ≈ 1.76 million shares. The transaction represents under 1 % of his total ownership and is not considered material.
BeOne Medicines (ONC) filed a routine Form 4 reporting a small insider transaction by President & COO Wu Xiaobin.
On 06/23/2025, Wu disposed of 1,363 American Depositary Shares at $260 per ADS (≈$0.35 million) to satisfy mandatory tax-withholding on vested RSUs. Post-sale holdings remain substantial at 1,228,328 ordinary shares plus 16,365 ADSs (4,000 held indirectly by spouse). No other changes to ownership, compensation, or governance were disclosed.
BeOne Medicines (ONC) filed a routine Form 4 disclosing that Director and Scientific Advisory Board Chair Xiaodong Wang sold an aggregate 2,007 American Depositary Shares (each equal to 13 ordinary shares) on 06/24/2025 under a Rule 10b5-1 plan at prices ranging from $263.40 – $267.81. The total consideration is roughly $0.53 million, representing about 0.3 % of his total beneficial ownership. No new grants, derivative transactions, or governance changes were reported.
BeOne Medicines (ONC) filed a routine Form 4 showing CEO/Director John Oyler’s mandatory tax-withholding sale of 3,174 American Depositary Shares (≈41,262 ordinary shares) on 06/23/2025 at an average price of about $262, totaling roughly $0.83 million.
Post-sale, Oyler still controls ≈54.2 million ordinary shares through direct and indirect holdings, so his ownership percentage is effectively unchanged. No other transactions or material changes were disclosed.
BeOne Medicines Ltd. has filed a Form 144 notice for the proposed sale of 2,007 American Depositary Shares (ADS) through Morgan Stanley Smith Barney LLC. The shares have an aggregate market value of $516,822.57 and are planned to be sold on the NASDAQ around June 24, 2025.
The securities were originally acquired as Restricted Stock Units from the issuer on June 15, 2025. The filing also discloses significant recent trading activity by XIAODONG WANG through a 10b5-1 trading plan, including:
- June 10, 2025: 41,760 ADS sold for $10,975,317.26
- May 13, 2025: 41,760 ADS sold for $9,333,272.30
- April 14, 2025: 41,760 ADS sold for $10,133,594.35
The total outstanding shares of the company are 56,964,739. This Form 144 represents the declaration of intention to sell securities acquired through RSUs, following a pattern of systematic sales through an established 10b5-1 trading plan.
FAQ
What is the current stock price of Beigene (ONC)?
What is the market cap of Beigene (ONC)?
